Tags

Type your tag names separated by a space and hit enter

Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases.
Autoimmunity. 2005 Feb; 38(1):105-9.A

Abstract

BACKGROUND

Multiplexed assays using fluorescence microspheres is an exciting technology with multiple applications including the detection of antinuclear autoantibodies (ANA) and autoantibody profiles. It is a rapid, sensitive and automatic method for simultaneous quantitative detection of several autoantibodies. The aim of our study was to determinate ANA and other autoantibodies to the nine extractable nuclear antigens by the AtheNA Multi-Lyte ANA system and compare the results achieved by this method to the routinely used enzyme immunoassay.

METHODS

Four hundred eighteen serum samples were tested utililizing the multiplexed method: 96 healthy donors, 86 requested ANA specimens obtained from routine lab, and 236 samples from patients with known autoimmune diseases (43-scleroderma, 113-systemic lupus erythematosus, 38-Sjogren's syndrome, and 42 rheumatoid arthritis). The ANA and antibodies to nine different analytes (SS/A, SS/B, Sm, RNP, Jo-1, Scl-70, dsDNA, Centromere B and Histone) were tested.

RESULTS

ANA screening by AtheNA system revealed high concordance of 99 and 97.7% with the enzyme immunoassay test in samples obtained from healthy donors and ANA requested samples, respectively. Evaluation of autoimmune disease-related samples for ANA by AtheNA technology also confirmed a high rate of concordance of 92-97.7% and correlated with the enzyme immunoassay. Positive discrepant results were found for Scl-70 specificity in 12.7% of SLE specimens by AtheNA technology, while all tested sera were negative for this antibody by enzyme immunoassay. Negative discrepant results were observed by the AtheNA system for anti-dsDNA. The sera (15 randomly obtained samples from SLE patients) were positive for anti-dsDNA in 50% of samples in Farr assay and 55% in enzyme immunoassay, respectively.

CONCLUSION

We suggest that the AtheNA technology may be a useful diagnostic tool for ANA screening. Additional investigations are required to compare an analytic performance between AtheNA and routine methods in determination of the individual autoantibody profile.

Authors+Show Affiliations

Department of Medicine B and Center for Autoimmune Diseases, Sackler Faculty of Medicine Sheba Medical Center Tel-Aviv University Tel-Hashomer Tel-Aviv Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article

Language

eng

PubMed ID

15804711

Citation

Shovman, O, et al. "Multiplexed AtheNA Multi-lyte Immunoassay for ANA Screening in Autoimmune Diseases." Autoimmunity, vol. 38, no. 1, 2005, pp. 105-9.
Shovman O, Gilburd B, Zandman-Goddard G, et al. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity. 2005;38(1):105-9.
Shovman, O., Gilburd, B., Zandman-Goddard, G., Yehiely, A., Langevitz, P., & Shoenfeld, Y. (2005). Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity, 38(1), 105-9.
Shovman O, et al. Multiplexed AtheNA Multi-lyte Immunoassay for ANA Screening in Autoimmune Diseases. Autoimmunity. 2005;38(1):105-9. PubMed PMID: 15804711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. AU - Shovman,O, AU - Gilburd,B, AU - Zandman-Goddard,G, AU - Yehiely,A, AU - Langevitz,P, AU - Shoenfeld,Y, PY - 2005/4/5/pubmed PY - 2005/7/1/medline PY - 2005/4/5/entrez SP - 105 EP - 9 JF - Autoimmunity JO - Autoimmunity VL - 38 IS - 1 N2 - BACKGROUND: Multiplexed assays using fluorescence microspheres is an exciting technology with multiple applications including the detection of antinuclear autoantibodies (ANA) and autoantibody profiles. It is a rapid, sensitive and automatic method for simultaneous quantitative detection of several autoantibodies. The aim of our study was to determinate ANA and other autoantibodies to the nine extractable nuclear antigens by the AtheNA Multi-Lyte ANA system and compare the results achieved by this method to the routinely used enzyme immunoassay. METHODS: Four hundred eighteen serum samples were tested utililizing the multiplexed method: 96 healthy donors, 86 requested ANA specimens obtained from routine lab, and 236 samples from patients with known autoimmune diseases (43-scleroderma, 113-systemic lupus erythematosus, 38-Sjogren's syndrome, and 42 rheumatoid arthritis). The ANA and antibodies to nine different analytes (SS/A, SS/B, Sm, RNP, Jo-1, Scl-70, dsDNA, Centromere B and Histone) were tested. RESULTS: ANA screening by AtheNA system revealed high concordance of 99 and 97.7% with the enzyme immunoassay test in samples obtained from healthy donors and ANA requested samples, respectively. Evaluation of autoimmune disease-related samples for ANA by AtheNA technology also confirmed a high rate of concordance of 92-97.7% and correlated with the enzyme immunoassay. Positive discrepant results were found for Scl-70 specificity in 12.7% of SLE specimens by AtheNA technology, while all tested sera were negative for this antibody by enzyme immunoassay. Negative discrepant results were observed by the AtheNA system for anti-dsDNA. The sera (15 randomly obtained samples from SLE patients) were positive for anti-dsDNA in 50% of samples in Farr assay and 55% in enzyme immunoassay, respectively. CONCLUSION: We suggest that the AtheNA technology may be a useful diagnostic tool for ANA screening. Additional investigations are required to compare an analytic performance between AtheNA and routine methods in determination of the individual autoantibody profile. SN - 0891-6934 UR - https://www.unboundmedicine.com/medline/citation/15804711/Multiplexed_AtheNA_multi_lyte_immunoassay_for_ANA_screening_in_autoimmune_diseases_ L2 - http://www.tandfonline.com/doi/full/10.1080/08916930400022707 DB - PRIME DP - Unbound Medicine ER -